SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

Community members are actively promoting the token as the foundational "source code" of internet meme culture, viewing its low market capitalization and high supply as a unique opportunity for extreme gains during the next market cycle. The conversation is dominated by bullish sentiment that links the project to the broader meme-sector ecosystem, with participants encouraging others to hold through periods of volatility.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna is experiencing a significant surge in trading volume and price momentum as the community highlights the stock's low float and strategic positioning as a natural gas supplier amidst deepening geopolitical instability in the Middle East. Traders are actively debating the potential for a sustained breakout, with many citing the company's European energy infrastructure assets and recent reports of increased natural gas reserves as key catalysts for current investor interest.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is currently experiencing heightened volatility and intense debate, with the community polarized between optimism regarding its institutional partnerships and high-speed blockchain claims versus skepticism over its recent price decline and reliance on aggressive social media promotion. While some participants view current dips as a generational entry point for long-term holders, others are actively questioning the project's transparency and progress on its technical roadmap.

Gold.com, Inc. engages in the trading of gold, silver, platinum, and palladium bullion numismatic coins, and related products. It operates through the following segments: Wholesale Trading and Ancillary Services, Direct-to-Consumer, and Secured Lending. The Wholesale Trading and Ancillary Services segment is involved in the distribution and purchasing of metal products from sovereign and private mints. The Direct-to-Consumer segment provides access to a multitude of products through its wholly owned subsidiaries. The Secured Lending segment includes coin and precious metal dealers, investors, and collectors. The company was founded by Steven C. Markoff on April 9, 1965 and is headquartered in El Segundo, CA.

Gold.com Inc.

Investors are currently monitoring $AMRK for its potential as a precious metals platform, particularly following its strategic acquisition of JM Bullion and recent shifts in analyst sentiment. The community is actively debating its valuation versus industry peers as the company navigates ongoing insider activity and precious metals market volatility.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as investors weigh its aggressive global expansionhighlighted by the recent BrewDog acquisitionagainst broader sector-wide volatility and ongoing speculation regarding U.S. cannabis rescheduling. While some in the community view these moves as a strategic pivot toward a diversified beverage empire, others express concern over dilution and the timeline for federal policy catalysts.

Bank of Montreal engages in the provision of banking and financial services to individuals and institutions. It operates through the following segments: Canadian Personal and Commercial Banking (Canadian P&C), United States Personal and Commercial Banking (U.S. P&C), BMO Wealth Management, BMO Capital Markets, and Corporate Services. The company was founded by Robert Armour, John C. Bush, Austin Cuvillier, George Garden, Horatio Gates, James Leslie, George Moffatt, John Richardson and Thomas A. Turner on June 23, 1817 and is headquartered in Toronto, Canada.

Bank of Montreal - MicroSectors Gold Miners 3X Leveraged ETN

GDXU is experiencing extreme volatility as traders weigh the impact of shifting geopolitical tensions and inflation data on precious metals against aggressive profit-taking. The community is sharply divided, with many debating whether to swing trade the rapid price swings or hold through the current uncertainty in anticipation of a larger gold market rally.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The Dow Jones Industrial Average is capturing attention following its historic milestone of closing above 50,000, a move fueled by investor optimism surrounding U.S. economic growth and the impact of corporate earnings. Market participants remain focused on potential volatility tied to ongoing geopolitical developments, shifting Federal Reserve rate expectations, and the broader debate over the sustainability of current AI-driven valuations versus industrial sector strength.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MercadoLibre is currently trending as investors debate the impact of aggressive reinvestment strategies into logistics and credit portfolio expansion on near-term profit margins. While the community remains divided over the stock's short-term volatility and institutional positioning, many traders are highlighting the company's dominant regional ecosystem and long-term growth potential as a primary catalyst for buying the dip.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as investors debate the potential impact of the Clarity Act on the token's long-term utility, with the community split between those accumulating at historic lows and others expressing deep frustration over prolonged price suppression. Conversations are currently dominated by intense speculation regarding institutional adoption, the future of the Anvil protocol, and the impact of potential regulatory breakthroughs in the coming months.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors monitor the early-stage commercial rollout of Yartemlea following recent FDA approval and anticipate the next potential milestone payments from the Novo Nordisk partnership. Community discussion is heavily focused on the stock's recent price volatility, which many long-term shareholders characterize as artificial suppression by short sellers, while they look for signs of sustained revenue growth and upcoming catalysts like EU regulatory updates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Pfizer reported positive Phase 2b topline results for its GLP-1 candidate in adults with obesity or overweight without type 2 diabetes.</li><li>The company plans to launch more than 20 trials in 2026, including 10 Phase 3 studies of PF’3944.</li><li>For the fourth-quarter (Q4), Pfizer posted a revenue of $17.6 billion, beating Wall Street estimates of $16.8 billion, according to Fiscal.ai data.</li></ul>Pfizer Inc. (PFE) stock was in the spotlight on Tuesday after the company reported positive updates from a study testing weight loss treatment and a better-than expected fourth quarter print.However, <a href="https://stocktwits.com/symbol/PFE">PFE shares</a> were down 2% in pre-market trading on Tuesday as investors appeared to remain cautious about growth risks and the long road ahead for its GLP-1 pipeline.&nbsp;<h2 class="st-heading-2">Positive Topline Results For Weight Loss Treatment&nbsp;</h2>Pfizer reported positive topline results from its Phase 2b VESPER-3 study evaluating PF’3944, an ultra-long-acting injectable GLP-1 receptor agonist, in adults with obesity or overweight without type 2 diabetes.The trial aimed to determine whether patients could maintain weight loss while switching from weekly to once-monthly injections and whether the treatment would retain a favorable safety profile.The study met its primary endpoint, delivering statistically significant weight reduction across all tested doses. Participants achieved up to 12.3% mean placebo-adjusted weight loss at week 28. PF’3944 was generally well tolerated, with mostly mild to moderate gastrointestinal side effects and limited treatment discontinuations. The safety profile remained consistent with the broader GLP-1 drug class.“Based on the monthly dosing efficacy and tolerability demonstrated in this trial, we remain confident in our plan to include a higher 9.6 mg monthly maintenance dose of PF’3944 in Phase 3,” said Jim List, Chief Internal Medicine Officer.Following its acquisition of Metsera and a global licensing deal with YaoPharma, Pfizer said it is accelerating its obesity treatment pipeline. The company plans to launch more than 20 trials in 2026, including 10 Phase 3 studies of PF’3944.<h2 class="st-heading-2">Q4 Earnings Snapshot</h2>Pfizer reaffirmed its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion and adjusted diluted earnings between $2.80 and $3 per share. The company said the outlook includes roughly $5 billion in expected COVID-19 product sales and a projected $1.5 billion year-over-year revenue hit from certain products losing exclusivity.The company posted a 2% decline in FY2025 revenue at $62.6 billion with adjusted earnings of $3.22 per share.For the fourth-quarter (Q4), Pfizer posted a revenue of $17.6 billion, beating Wall Street estimates of $16.8 billion, according to Fiscal.ai data. It also posted a better-than-expected EPS of $0.66.<h2 class="st-heading-2">What Did Stocktwits Users Say?</h2>Retail sentiment on Stocktwits remained in the ‘bullish’ territory over the past 24 hours, amid ‘high’ message volumes. PFE was among the top trending tickers on the platform.<figure class="image"><img src="https://news.stocktwits-cdn.com/PFE_jpg_91e98a5cdf.webp" alt="PFE.jpg" width="928" height="111"><figcaption>PFE's Sentiment Meter and Message Volumes in Pre-Market on Feb. 3, 2026 | Source: Stocktwits</figcaption></figure>One user expects multiple upcoming catalysts this year for the stock.<stembedurl>https://stocktwits.com/giuseppe8469/message/643776399</stembedurl>Another user highlighted key support and resistance levels.<stembedurl>https://stocktwits.com/Jas45z/message/643776263</stembedurl>The stock has gained around 1.5% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/sofi-stock-rises-pre-market-what-moving-average-indicates/cZbiqlvR4ln">SOFI Stock Hovers Around 200-DMA — A Make-or-Break Test Looms</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Pfizer’s logo is on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Pfizer Reports Positive Weight-Loss Trial Results, Strong Q4 – So Why Is PFE Stock Falling?

Pfizer reaffirmed its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion, while its FY2025 revenue came in at $62.6 billion.

Equity

Pharma ETF (FTXH) Hits New 52-Week High

Pharma ETF FTXH hits a new 52-week high as industry momentum, rate cuts, and AI adoption lift the sector???signaling potential near-term upside for FTXH investors.



Pharma ETFs in Spotlight Following Robust Q3 Earnings Results

Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month 

As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.  

ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook

 JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.


Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit

Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.     

ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook

IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.


What Are Wall Street Analysts' Target Price for Bristol-Myers Squibb Stock?

Pharma giant Bristol-Myers Squibb has notably outpaced the broader pharma industry over the past year and analysts remain moderately bullish on the stock’s prospects.

Current Price	$32.95
Prev Close	$33.38
Open	$33.22
Dividend Yield	N/A
50-Day Moving Average	$34.32
Beta	N/A
Avg. Volume	12,623.54
PE Ratio	N/A

52-Week High	$35.61
52-Week Low	$23.29
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

FTXH
First Trust Exchange-Traded Fund III - First Trust Nasdaq Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Latest FTXH News

FTXHFirst Trust Exchange-Traded Fund III - First Trust Nasdaq Pharmaceuticals ETF